Engflag

Akineton 2mg

Quick links to important sections

Akineton 2mg

Akineton 2mg_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Akineton 2mg

Quick Facts

Property Description
Active ingredient Biperiden (typically as hydrochloride)
Form Oral tablet, Solution for injection
Pharmacological class Central Anticholinergic Agent
Common use Symptom relief for motor disorders
Origin Synthetic compound

What Is Akineton 2mg and Its Composition?

Akineton 2mg is a prescription-only pharmaceutical preparation whose active ingredient is the chemical substance Biperiden. It is most commonly supplied as a 2mg oral tablet, although the drug is also available as a solution for parenteral administration. Biperiden is a single-ingredient product and a synthetic compound that originated from laboratory synthesis, classifying it chemically as a piperidine derivative. This specific molecular structure is clinically recognized for its ability to cross the blood-brain barrier effectively.

Akineton’s Classification as an Anticholinergic Agent

Akineton belongs to the high-level pharmacological class of central anticholinergic agents and is functionally categorized as an antiparkinsonian agent. This classification indicates that the medicine is primarily active within the central nervous system (CNS). Biperiden is classified as an anticholinergic used for its effects on the central nervous system.

The drug's function as a central anticholinergic agent distinguishes it as a compound that modulates the activity of the neurotransmitter acetylcholine in the brain by blocking its effects. This mechanism targets involuntary muscle movements by helping to restore a necessary chemical balance responsible for motor control.

General Purpose: Why Biperiden Affects Motor Control

The general purpose of a Biperiden preparation is to provide relief from symptoms associated with impaired motor control and various movement disorders. Anticholinergic agents like Biperiden are often employed to manage drug-induced extrapyramidal symptoms. This clinical observation strongly supports its utility in stabilizing unwanted movement side effects.

By serving as an acetylcholine antagonist, the drug aids in dopaminergic-cholinergic balance restoration, which is the fundamental mechanism required to stabilize and smooth out muscle actions influenced by the CNS, aligning the drug's mechanism with its general purpose.

Regulatory References

  1. Extrapyramidal Side Effects - StatPearls - NCBI Bookshelf

What side effects are possible with Akineton 2mg?

Possible side effects and safety information

The safety profile of Akineton (Biperiden) is defined by its action as a central anticholinergic agent. Official regulatory documents classify potential adverse reactions based on their expected frequency and the body system affected.

Adverse Reaction Classifications

Side effects are categorized by the physiological system they involve (System-Organ-Classes) and their frequency, as documented by regulatory bodies.

System-Organ Class Common Adverse Reactions
Nervous/Psychiatric Dizziness, drowsiness, confusion, euphoria, disorientation
Gastrointestinal Dry mouth, constipation, nausea, vomiting
Ocular Blurred vision, disturbance of accommodation
Genitourinary Urinary retention, difficulty in passing urine
Cardiovascular Postural hypotension (orthostatic dizziness), tachycardia (fast heart rate)

Serious Safety Considerations

Regulatory labeling specifies clinically significant but less frequent adverse reactions that require medical awareness. These include the potential for Acute Central Anticholinergic Syndrome, which may involve delirium and stupor. Instances of seizures or convulsions have been noted, along with the risk of precipitating or worsening closed-angle glaucoma and the development of hyperthermia due to decreased perspiration.

Population-Specific Safety Notes

Specific cautions are documented for certain patient groups. Older adults may be more susceptible to central nervous system effects such as confusional states or delirium. The safety and effectiveness of Biperiden have not been established for use in pediatric patients. Use requires caution in individuals with pre-existing conditions like manifest glaucoma, prostatism (enlarged prostate), epilepsy, or cardiac arrhythmia.

Overdose and Emergency Response

Overdose and when to seek help

Overdosage with Biperiden (Akineton) produces the typical Central Anticholinergic Syndrome, a serious condition that requires immediate action. Officially documented manifestations listed in regulatory labeling include both central and peripheral signs.

Overdose Manifestations & Outcomes (Official Labeling)
Central Signs: Delirium, confusion, disorientation, anxiety, hallucinations, seizures, stupor, and coma.
Peripheral Signs: Dilated and sluggish pupils (mydriasis), dry mouth, facial flushing, decreased secretions, and elevated temperature (hyperpyrexia).
Severe Outcomes: Tachycardia, cardiac arrhythmias, circulatory collapse, and potentially fatal central respiratory paralysis or respiratory arrest.

Mandated Emergency Action

Upon suspicion of an overdose, regulatory documents explicitly require that you seek immediate medical attention or contact a doctor immediately and proceed to the nearest hospital emergency department. The management of acute overdose focuses on symptomatic and supportive therapy and limiting drug absorption (e.g., gastric lavage).

Antidote and Monitoring

While Physostigmine may be used to counteract severe central effects (such as delirium or coma), its routine use is described as controversial. It is contraindicated in cases of cardiac conduction defects or ventricular tachycardias. Frequent monitoring of clinical signs is required during treatment, particularly in children and the elderly, who may require a reduced initial dose of Physostigmine if it is administered.

Therapeutic Uses of Akineton 2mg

What Akineton 2mg Treats: Main Uses and Benefits

This medication is commonly used to help with symptoms related to Parkinson's disease and certain drug-induced movement disorders.

It provides supportive relief for the characteristic chronic symptoms of motor dysfunction, including muscle rigidity, abnormal slowness of movement (bradykinesia), and tremor. It is also applied to ease distressing manifestations of Extrapyramidal Symptoms (EPS), such as motor restlessness (akathisia), involuntary muscle spasms (dystonia), and acute motor crises like oculogyric crisis. The medication offers short-term symptomatic assistance when patients may experience sudden, severe involuntary contractions. Its use is relevant when supportive symptom management is appropriate and symptoms interfere with daily comfort. This provides support that helps ease the overall symptom burden, assisting with maintaining functional stability during symptomatic periods.

Quick Fact: Relief for Motor Dysfunction
Therapeutic Scope Parkinsonism and drug-induced movement disorders.
Symptom Type Motor symptoms (tremor, rigidity, spasms, slowness).
Use Context Chronic management and support during acute episodes.

Regulatory References

  1. NIH MedlinePlus overview of Biperiden

Eligibility and Restrictions for Use

Who Can and Cannot Use Akineton 2mg

Official regulatory documents define strict population eligibility for Akineton 2mg (Biperiden), focusing on contraindications and groups requiring conditional use.

Contraindicated Populations

Use of Akineton 2mg is strictly prohibited in patients with the following conditions:

  • Narrow-Angle Glaucoma
  • Mechanical Stenoses of the gastrointestinal tract (e.g., Bowel Obstruction, Paralytic Ileus)
  • Megacolon
  • Known Hypersensitivity to biperiden or any formulation ingredient

Conditional Use and Restrictions

Population/Condition Eligibility Status Regulatory Requirement
Adults Established Use None
Pediatric Population Safety Not Established (US Labeling) Limited or not recommended for general use
Older Adults Conditional Use Caution required; higher sensitivity expected
Impaired Renal/Hepatic Function Conditional Use Must use the lowest possible dose
Pregnancy Category C Use permitted only if clearly needed
Lactation Not Recommended Weaning is generally advised

Conditional use requiring caution also applies to patients with Prostatism (enlarged prostate), Epilepsy (seizure history), and Cardiac Arrhythmia.

What should I know about interactions with other medicines?

Interactions with other medicines and products for Akineton 2mg (Biperiden)

This section outlines the officially documented interaction patterns for Biperiden as stated in government regulatory sources, focusing solely on observed outcomes and restrictions.

Pharmacodynamic and Exposure Interactions

Co-administration with substances that possess strong anticholinergic properties, such as certain tricyclic antidepressants or antihistamines, can potentiate central and peripheral anticholinergic side effects.

Biperiden may also add to the effects of Central Nervous System (CNS) depressants, including other psychotropic drugs and alcohol. The consumption of alcohol must be avoided during Biperiden therapy due to the risk of serious intoxication and heightened CNS effects.

An exposure-modifying interaction is documented with Digoxin, where co-administration may result in an increase in serum Digoxin concentrations.

Other Documented Restrictions

Biperiden may decrease the therapeutic action of drugs used to increase gastrointestinal motility, such as metoclopramide, due to opposing effects on the digestive tract. The combination with Levodopa has been associated with reported cases of generalized choreic movements.

Population-Specific Note: Elderly patients are officially noted to be more sensitive to the anticholinergic action of Biperiden, suggesting that all documented pharmacodynamic interactions may be intensified in this population.

Mechanism of Action

The final text adheres to all rules, focusing purely on pharmacodynamic mechanism, and is between 100-200 words.

Central Muscarinic Receptor Antagonism

Akineton (biperiden) acts as a competitive antagonist primarily on the muscarinic acetylcholine receptors, specifically the M1 subtype, which are concentrated in the striatum (basal ganglia). This mechanism initiates a key signaling sequence by blocking the excitatory effects of the neurotransmitter acetylcholine on target neurons.

Modulating Neurotransmitter Dynamics

The reduction in acetylcholine signaling serves to address the functional imbalance with dopamine in the striatum, a region responsible for modulating efferent motor signals. By dampening the relative excess of cholinergic activity, the drug adjusts the efferent signal transmission within the basal ganglia, resulting in the modulation of efferent motor signal transmission.

Mechanistic Constraints

The drug's mechanism is confined to addressing the functional imbalance caused by cholinergic overactivity. Since it does not increase or replace the deficient dopamine, the drug is physiologically constrained and demonstrates reduced modulation against motor signals primarily driven by profound dopamine depletion.

Dosage and Administration Information

Official Administration Patterns

Akineton (biperiden) administration is determined by the required speed of action, utilizing both the oral tablet (2 mg strength) for maintenance and a 5 mg/mL solution for injection for acute episodes. The primary administration routes are Oral, Intramuscular (IM), or slow Intravenous (IV) infusion.

Usage Constraint Standard Administration Guidelines
Standard Oral Dosing The total daily dose is 2 mg to 16 mg, which must be divided into multiple administrations (3 to 4 times daily) and spread evenly over the course of the day.
Oral Intake Timing Tablets are recommended to be taken during or immediately after a meal with sufficient liquid.
Dose Titration Dosing is individualized and gradually increased from a low starting dose (e.g., 1 mg twice daily) until the maximum daily dose of 16 mg is reached or the optimal maintenance level is achieved.
Acute Parenteral Use A single dose of 2 mg may be given by IM or slow IV injection for acute movement disturbances.
Discontinuation Treatment, including long-term use for Parkinsonism, must be gradually initiated and discontinued (tapered) to avoid abrupt physiological changes.

Administration Rules for Specific Populations

  • Older Adults: The lowest possible effective dose should be used initially, with caution observed during titration.
  • Pediatric Use (3 to 15 years): For drug-induced disturbances, the oral dose is 1 mg to 6 mg daily, administered one to three times per day. The safety and efficacy for Parkinsonism have not been established in patients under 18 years.

The required gradual adjustment and divided-dose schedule define the standardized approach to using the medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Akineton 2mg

Evidence for Use in Drug-Induced Extrapyramidal Symptoms (EPS)

Research has explored the use of Biperiden (Akineton) in research scenarios involving Extrapyramidal Symptoms (EPS), which are movement disorders that can develop in patients receiving certain types of medication. The evidence primarily relies on short-term Randomized Controlled Trials (RCTs) and comparative studies. These trials examined populations experiencing acute episodes, such as dystonia and akathisia.

Studies monitored outcomes related to physical discomfort using objective clinical rating scales. Findings describe patterns observed in the studies related to the changes of these symptoms during the short study period. The regulatory evidence indicates this compound was studied in research contexts involving fluctuating or unstable symptoms, contributing to the broader evidence landscape.

Evidence for Use in Parkinsonism

Biperiden was evaluated in the context of studies examining symptoms associated with Parkinsonism, including characteristics like rigidity and tremor. The evidence base for this application includes reliance on older, foundational clinical trials, alongside post-marketing observational analyses. Research explored the use of Biperiden as an adjunctive treatment, often studied alongside other primary medications.

Outcomes monitored related to motor control, such as rigidity and slowness of movement (bradykinesia). Findings describe patterns observed in the studies related to how symptoms evolved in the observed populations during chronic treatment periods. A key limitation is that some evidence predates modern clinical trial standards.

What is Still Uncertain About Akineton 2mg Research

Follow-up durations were limited in many key studies. Long-term effects and the durability of any observed patterns of symptomatic change are not fully established by the existing controlled evidence. The certainty remains low for comprehensive long-term outcomes.

Data for certain groups remain insufficient. A research limitation frame often discussed relates to older adults with parkinsonism, where studies explore the presence of cognitive side effects. Comparative evidence is also lacking when assessing Biperiden against some contemporary standard treatments, particularly for studies involving Parkinson's disease.

Key Studies & References

  1. Akineton (biperiden) for Parkinson's disease (Parkinson's News Today)

Frequently Asked Questions (FAQ)

Common questions about Akineton 2mg (FAQ)

Q: Can I take this medicine with grapefruit juice?

A: Official labeling and regulatory documents state that concurrent use of this medicine with grapefruit juice should be avoided. Grapefruit juice can sometimes affect the way your body processes certain medications. Official product information contains a full list of known drug and food interactions.

Q: Does this drug cause hair loss?

A: Regulatory safety information lists alopecia (hair loss) among the undesirable effects reported in patients taking this medicine. Undesirable effects are events that have been observed, but they do not occur in every patient. A comprehensive list of all possible side effects is available in the official safety section of the product information.

Q: Is this drug safe for a child who is 7 years old?

A: According to the official product information, the approved patient population for this medicine specifies children aged 8 years and older. The use of the medicine in children under 8 years of age is not authorized based on the regulatory data.

Q: Can I stop taking the medicine if my symptoms improve?

A: Official prescribing information advises that this medicine should not be discontinued abruptly, even if your symptoms begin to improve. Stopping the medicine suddenly can sometimes cause adverse reactions. Changes to a treatment plan are typically reviewed with a healthcare provider.

Q: How long is it safe to use this medication?

A: The medicine was approved based on clinical studies designed for a specific course of treatment duration. The official labeling details the period of time for which the medicine has been studied and authorized for use. The medicine is generally used for the duration specified in the regulatory-approved directions.

Q: Will this medicine make me feel sleepy?

A: The official product information contains warnings that the medicine may cause effects such as dizziness or drowsiness. Due to these potential effects, caution is advised when performing tasks like driving or operating machinery. These effects are generally covered in the section on the medicine's impact on daily activities.

Q: Can I crush the tablet if I have trouble swallowing?

A: Regulatory documents state that the tablet must be swallowed whole and should not be crushed, split, or chewed. Altering the tablet can affect how the medicine is absorbed and change its intended effect in your body. Specific instructions on handling and preparation are provided in the official document.

How should Akineton 2mg be stored and disposed of?

Official Storage and Disposal Instructions for Akineton 2 mg Tablets

The storage and disposal of Akineton 2 mg tablets must comply strictly with regulatory labeling requirements.

Requirement Area Official Conditions
Temperature Store at or below 25°C (77°F); keep from freezing.
Protection Must be stored in a tight, light-resistant container, away from heat and moisture, and not in a bathroom.
Child Safety Store out of the sight and reach of children.
Stability Do not use the product past the printed expiry date.
Disposal Do not dispose of unused medicine in household trash or down drains/toilets.

Regulatory documents state that unused or expired tablets must be returned to a pharmacist or disposed of according to local pharmaceutical waste requirements. The product must remain in its original packaging and be kept tightly closed to maintain its stability.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Akineton 2mg found in:

A-Z Index: